Editas Medicine: HC Wainwright Raises PT to $5 from $4 on Buy Rating
ByAinvest
Friday, Sep 5, 2025 7:18 am ET1min read
EDIT--
Editas Medicine is a clinical-stage genome editing company focused on developing transformative genomic medicines to treat a broad range of serious diseases. The company's proprietary gene editing platform is based on CRISPR technology, which uses a protein-RNA complex to recognize and edit specific DNA sequences [2].
The latest earnings report from Editas Medicine indicated a loss of $0.63 per share, missing analysts' estimates, but exceeding revenue expectations with $3.58 million reported [3]. Despite the earnings miss, the company's strong cash position and operational runway into the second quarter of 2027 suggest that it is well-positioned for future growth [4].
The consensus recommendation from brokerage firms is currently "Hold," with an average 12-month price target of $5.10 [3]. However, the recent price target increase by HC Wainwright indicates a shift in sentiment among analysts.
Editas Medicine's lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD) and transfusion-dependent beta-thalassemia [2]. The company is also developing EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis.
The stock has shown volatility in recent months, trading between $0.91 and $4.12 over the past year. Institutional investors own 71.90% of the company's stock [3].
References:
[1] https://www.gurufocus.com/news/3092849/editas-medicine-edit-sees-analyst-price-target-raised-by-wells-fargo-edit-stock-news
[2] https://www.marketscreener.com/news/editas-medicine-picks-edit-401-gene-editing-drug-as-lead-in-vivo-development-candidate-ce7c50d3de8bf123
[3] https://www.marketbeat.com/instant-alerts/editas-medicine-inc-nasdaqedit-receives-consensus-recommendation-of-hold-from-analysts-2025-08-31/
[4] https://www.morningstar.com/news/globe-newswire/9521261/editas-medicine-nominates-edit-401-an-ldlr-targeted-medicine-as-lead-in-vivo-development-candidate
Editas Medicine: HC Wainwright Raises PT to $5 from $4 on Buy Rating
HC Wainwright & Co. has raised its price target for Editas Medicine (EDIT) to $5.00 from $4.00, maintaining a "Buy" rating on the stock [1]. This adjustment marks a 25% increase in the target price, reflecting a more optimistic outlook on the stock's potential performance.Editas Medicine is a clinical-stage genome editing company focused on developing transformative genomic medicines to treat a broad range of serious diseases. The company's proprietary gene editing platform is based on CRISPR technology, which uses a protein-RNA complex to recognize and edit specific DNA sequences [2].
The latest earnings report from Editas Medicine indicated a loss of $0.63 per share, missing analysts' estimates, but exceeding revenue expectations with $3.58 million reported [3]. Despite the earnings miss, the company's strong cash position and operational runway into the second quarter of 2027 suggest that it is well-positioned for future growth [4].
The consensus recommendation from brokerage firms is currently "Hold," with an average 12-month price target of $5.10 [3]. However, the recent price target increase by HC Wainwright indicates a shift in sentiment among analysts.
Editas Medicine's lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD) and transfusion-dependent beta-thalassemia [2]. The company is also developing EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis.
The stock has shown volatility in recent months, trading between $0.91 and $4.12 over the past year. Institutional investors own 71.90% of the company's stock [3].
References:
[1] https://www.gurufocus.com/news/3092849/editas-medicine-edit-sees-analyst-price-target-raised-by-wells-fargo-edit-stock-news
[2] https://www.marketscreener.com/news/editas-medicine-picks-edit-401-gene-editing-drug-as-lead-in-vivo-development-candidate-ce7c50d3de8bf123
[3] https://www.marketbeat.com/instant-alerts/editas-medicine-inc-nasdaqedit-receives-consensus-recommendation-of-hold-from-analysts-2025-08-31/
[4] https://www.morningstar.com/news/globe-newswire/9521261/editas-medicine-nominates-edit-401-an-ldlr-targeted-medicine-as-lead-in-vivo-development-candidate
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet